International Orthopaedics

, Volume 39, Issue 7, pp 1329–1334 | Cite as

Effectiveness of polydeoxyribonucleotide injection versus normal saline injection for treatment of chronic plantar fasciitis: a prospective randomised clinical trial

  • Jae Kwang KimEmail author
  • Jae Yoon Chung
Original Paper



Polydeoxyribonucleotide (PDRN) has been used for the treatment of chronic tendinosis. This prospective randomised study was conducted to evaluate the efficacy and complications of PDRN injection for treatment of plantar fasciitis.


Forty patients with a clinical diagnosis of plantar fasciitis were randomly allocated to PDRN injection (PDRN group, n = 20) or normal saline injection (placebo group, n = 20). Injections were performed weekly for three weeks. Clinical evaluations were done at baseline and four and 12 weeks after treatment began using the visual analogue scale (VAS) for foot pain and Manchester-Oxford Foot Questionnaire (MOXFQ). We also monitored the complications in both groups at one, two, four and 12 weeks after initial treatment.


The PDRN group achieved a significant improvement in VAS and MOXFQ scores at four weeks after treatment, and this improvement continued until 12 weeks after treatment. On the other hand, the placebo group did not achieve a significant improvement in the VAS or MOXFQ scores at four or 12 weeks. The initial VAS and MOXFQ scores of the PDRN group were not significantly different from those of the placebo group. At four weeks after treatment, the VAS and MOXFQ scores of the PDRN group were better than those of the placebo group, but the difference was not statistically significant. At 12 weeks after treatment, the VAS and MOXFQ scores of the PDRN group were significantly better than those of the placebo group. We noticed no injection-related complications, such as itching, urticaria, redness or infection signs around the injection site in either group.


PDRN injection is an effective and safe treatment option and may be considered for plantar fasciitis.


Plantar fasciitis Polydeoxyribonucleotide 



This study was supported by a research grant from Pharma Research Products and all of the PDRN injections were donated by Pharma Research Products.


  1. 1.
    Riddle DL, Pulisic M, Pidcoe P, Johnson RE (2003) Risk factors for plantar fasciitis: a matched case–control study. J Bone Joint Surg Am 85-A(5):872–877PubMedGoogle Scholar
  2. 2.
    McMillan AM, Landorf KB, Gilheany MF, Bird AR, Morrow AD, Menz HB (2012) Ultrasound guided corticosteroid injection for plantar fasciitis: randomised controlled trial. BMJ 344:e3260PubMedCrossRefGoogle Scholar
  3. 3.
    Goff JD, Crawford R (2011) Diagnosis and treatment of plantar fasciitis. Am Fam Physician 84(6):676–682PubMedGoogle Scholar
  4. 4.
    Neufeld SK, Cerrato R (2008) Plantar fasciitis: evaluation and treatment. J Am Acad Orthop Surg 16(6):338–346PubMedGoogle Scholar
  5. 5.
    Gill LH (1997) Plantar fasciitis: diagnosis and conservative management. J Am Acad Orthop Surg 5(2):109–117PubMedGoogle Scholar
  6. 6.
    Díaz-Llopis IV, Rodríguez-Ruíz CM, Mulet-Perry S, Mondéjar-Gómez FJ, Climent-Barberá JM, Cholbi-Llobel F (2012) Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months. Clin Rehabil 26(7):594–606. doi: 10.1177/0269215511426159 PubMedCrossRefGoogle Scholar
  7. 7.
    Rompe JD, Furia J, Weil L, Maffulli N (2007) Shock wave therapy for chronic plantar fasciopathy. Br Med Bull 81–82:183–208. doi: 10.1093/bmb/ldm005 PubMedCrossRefGoogle Scholar
  8. 8.
    Thomson CE, Crawford F, Murray GD (2005) The effectiveness of extra corporeal shock wave therapy for plantar heel pain: a systematic review and meta-analysis. BMC Musculoskelet Disord 6:19. doi: 10.1186/1471-2474-6-19 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Altavilla D, Bitto A, Polito F, Marini H, Minutoli L, Di Stefano V, Irrera N, Cattarini G, Squadrito F (2009) Polydeoxyribonucleotide (PDRN): a safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers. Cardiovasc Hematol Agents Med Chem 7(4):313–321PubMedCrossRefGoogle Scholar
  10. 10.
    Polito F, Bitto A, Galeano M, Irrera N, Marini H, Calò M, Squadrito F, Altavilla D (2012) Polydeoxyribonucleotide restores blood flow in an experimental model of ischemic skin flaps. J Vasc Surg 55(2):479–488. doi: 10.1016/j.jvs.2011.07.083 PubMedCrossRefGoogle Scholar
  11. 11.
    Bitto A, Polito F, Irrera N, D’Ascola A, Avenoso A, Nastasi G, Campo GM, Micali A, Bagnato G, Minutoli L, Marini H, Rinaldi M, Squadrito F, Altavilla D (2011) Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A((2)A) receptor. Arthritis Rheum 63(11):3364–3371. doi: 10.1002/art.30538 PubMedCrossRefGoogle Scholar
  12. 12.
    Gervaso P (2014) Use of polydeoxyribonucleotide for peritendon injection treatment. Minerva Ortop Traumatol 65(1):51–56Google Scholar
  13. 13.
    Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, Jenkinson C (2012) Responsiveness of the Manchester-Oxford Foot Questionnaire (MOXFQ) compared with AOFAS, SF-36 and EQ-5D assessments following foot or ankle surgery. J Bone Joint Surg Br 94(2):215–221. doi: 10.1302/0301-620x.94b2.27634 PubMedCrossRefGoogle Scholar
  14. 14.
    Dawson J, Coffey J, Doll H, Lavis G, Cooke P, Herron M, Jenkinson C (2006) A patient-based questionnaire to assess outcomes of foot surgery: validation in the context of surgery for hallux valgus. Qual Life Res 15(7):1211–1222. doi: 10.1007/s11136-006-0061-5 PubMedCrossRefGoogle Scholar
  15. 15.
    Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, Jenkinson C (2014) Minimally important change was estimated for the Manchester-Oxford Foot Questionnaire after foot/ankle surgery. J Clin Epidemiol 67(6):697–705. doi: 10.1016/j.jclinepi.2014.01.003 PubMedCrossRefGoogle Scholar
  16. 16.
    Cutts S, Obi N, Pasapula C, Chan W (2012) Plantar fasciitis. Ann R Coll Surg Engl 94(8):539–542. doi: 10.1308/003588412X13171221592456 PubMedCentralPubMedGoogle Scholar
  17. 17.
    Lemont H, Ammirati KM, Usen N (2003) Plantar fasciitis: a degenerative process (fasciosis) without inflammation. J Am Podiatr Med Assoc 93(3):234–237PubMedCrossRefGoogle Scholar
  18. 18.
    Crawford F, Atkins D, Young P, Edwards J (1999) Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford) 38(10):974–977CrossRefGoogle Scholar
  19. 19.
    Buchbinder R (2004) Clinical practice. Plantar fasciitis. N Engl J Med 350(21):2159–2166. doi: 10.1056/NEJMcp032745 PubMedCrossRefGoogle Scholar
  20. 20.
    Acevedo JI, Beskin JL (1998) Complications of plantar fascia rupture associated with corticosteroid injection. Foot Ankle Int 19(2):91–97PubMedCrossRefGoogle Scholar
  21. 21.
    Martinelli N (2014) Reply to letter to the editor: platelet-rich plasma injections for chronic plantar fasciitis. Int Orthop 38(1):203. doi: 10.1007/s00264-013-2130-z PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Sharma D (2013) Platelet-rich-plasma injections for chronic plantar fasciitis. Int Orthop 37(12):2543. doi: 10.1007/s00264-013-2128-6 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Soni A, Rajoli SR (2014) Comment on Sharma: platelet-rich-plasma injections for chronic planter fasciitis. Int Orthop 38(3):683. doi: 10.1007/s00264-013-2258-x PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Martinelli N, Marinozzi A, Carni S, Trovato U, Bianchi A, Denaro V (2013) Platelet-rich plasma injections for chronic plantar fasciitis. Int Orthop 37(5):839–842. doi: 10.1007/s00264-012-1741-0 PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Monto RR (2014) Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. Foot Ankle Int 35(4):313–318. doi: 10.1177/1071100713519778 PubMedCrossRefGoogle Scholar
  26. 26.
    Ragab EM, Othman AM (2012) Platelets rich plasma for treatment of chronic plantar fasciitis. Arch Orthop Trauma Surg 132(8):1065–1070. doi: 10.1007/s00402-012-1505-8 PubMedCrossRefGoogle Scholar
  27. 27.
    Placzek R, Deuretzbacher G, Buttgereit F, Meiss AL (2005) Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up. Ann Rheum Dis 64(11):1659–1661. doi: 10.1136/ard.2005.035840 PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Placzek R, Deuretzbacher G, Meiss AL (2006) Treatment of chronic plantar fasciitis with botulinum toxin A: preliminary clinical results. Clin J Pain 22(2):190–192PubMedCrossRefGoogle Scholar
  29. 29.
    Peterlein CD, Funk JF, Hölscher A, Schuh A, Placzek R (2012) Is botulinum toxin A effective for the treatment of plantar fasciitis? Clin J Pain 28(6):527–533. doi: 10.1097/AJP.0b013e31823ae65a PubMedCrossRefGoogle Scholar
  30. 30.
    Porta N, Bonet C, Cobo E (2007) Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 60(7):663–669. doi: 10.1016/j.jclinepi.2006.09.013 PubMedCrossRefGoogle Scholar

Copyright information

© SICOT aisbl 2015

Authors and Affiliations

  1. 1.Department of Orthopedic SurgeryEwha Womans University School of MedicineYangcheon-guSouth Korea

Personalised recommendations